drugset / Trial / NCT05625412
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in participants with advanced solid tumors.
Timeline
- Start
- 2022-12-09
- Primary completion
- 2025-05-12
- Completion
- 2025-05-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CC-90001 | Small molecule | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |